Tethis

Tethis is a provider of automated pre-analytical solutions for liquid biopsy, designed to preserve sample integrity through immediate, automated, and standardized processing of blood samples at the collection site. The company core technology includes SmartBioSurface slides featuring proprietary titanium nanocoating, and the See.d workstation that separates plasma and stabilizes the cellular fraction directly on nanocoated slides, ideal for detecting circulating tumor cells (CTCs) and preserving cell-free plasma. Tethis also offers a Digital Suite for downstream analysis. The platform aims to make liquid biopsy widely available in clinical practice by revolutionizing cancer management through earlier detection and better treatment guidance. Tethis has expanded global access to SmartBioSurface through channel partners in Brazil, India, China, and South Africa, and has announced application notes for cell suspension workflows on leading spatial biology platforms. Founded in 2004 and headquartered in Milan, Italy, Tethis has raised approximately 5.3 million in a Series A round with investors including EIC Fund, Indaco Venture Partners, ENEA Tech e Biomedical, Genextra, and IMI Fondi Chiusi SGR.

Nanotechnology > Nanoenabled Products > Life Science > Diagnostic > Point of Care,

Oncology > In-Vitro Diagnostic Tests > Pan Cancer